Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -57.13% | 1,125.78% | 4.89% | 318.14% | 26,714.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.13% | 1,125.78% | 4.89% | 318.14% | 26,714.86% |
| Cost of Revenue | -8.13% | -1.77% | 11.50% | 17.28% | 41.40% |
| Gross Profit | -63.32% | 19.89% | -12.96% | -15.62% | 42.30% |
| SG&A Expenses | 58.85% | 82.84% | 47.14% | 22.60% | 29.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.56% | 29.11% | 25.75% | 19.42% | 36.69% |
| Operating Income | -60.68% | -17.98% | -28.28% | -18.43% | 14.34% |
| Income Before Tax | -47.92% | -27.67% | -22.00% | -90.71% | 6.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.92% | -27.67% | -22.00% | -90.71% | 6.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.92% | -27.67% | -22.00% | -90.71% | 6.24% |
| EBIT | -60.68% | -17.98% | -28.28% | -18.43% | 14.34% |
| EBITDA | -60.72% | -17.55% | -28.43% | -18.56% | 14.51% |
| EPS Basic | -33.78% | -22.72% | -19.95% | -87.06% | 14.27% |
| Normalized Basic EPS | -33.78% | -22.72% | -19.95% | -12.98% | 14.27% |
| EPS Diluted | -33.78% | -22.72% | -19.95% | -87.06% | 14.27% |
| Normalized Diluted EPS | -33.78% | -22.72% | -19.95% | -12.98% | 14.27% |
| Average Basic Shares Outstanding | 10.57% | 4.03% | 1.72% | 1.95% | 9.35% |
| Average Diluted Shares Outstanding | 10.57% | 4.03% | 1.72% | 1.95% | 9.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |